×

INC Research's Jean Chitwood Named to Annual PharmaVOICE 100

RALEIGH, N.C., Aug. 02, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced Jean Chitwood, Executive Vice President, Corporate Strategy and Development, has been named to this year’s PharmaVOICE 100 list celebrating influential and inspirational leaders throughout the life sciences industry. An executive with INC Research for nearly 10 years, Ms. Chitwood was recognized for her strategic vision, passion and focus on helping her peers advance the Company and build INC Research into a successful global enterprise with an unmatched focus on investigative site relationships.

“Jean has imparted a true passion for strengthening INC by helping to formalize and engage our organization in the development and delivery of our business strategy to achieve our goals,” said Chief Executive Officer Jamie Macdonald. “Her strategic vision is a driving force within our Company. She is always looking ahead to ensure INC is evolving with the environment and is in the best possible position to serve customers and patients both now and in the future. Jean has been integral in infusing a “Can do, I own it” mindset into our corporate culture, so we are proud to see her contributions honored and can think of no one more deserving of this recognition.”

Ms. Chitwood has more than 25 years of healthcare experience with a variety of roles across the academia, pharmaceutical and CRO sectors. Her diverse background has provided her with a unique perspective that extends across all of INC Research’s business areas. Most notably, Ms. Chitwood has elevated the importance of sites and patients as a key focus of the Company’s overarching business strategy, spearheading numerous initiatives to strengthen relationships with sites and groups that elevate the voice of sites globally to make clinical trials better for patients and the clinicians who work on the front lines. She also has been instrumental in managing the integration of key transformational acquisitions that have propelled INC to become a top global CRO.

Since 2005, PharmaVOICE has released the 100 list to celebrate individuals throughout the life-sciences industry who provide inspiration to their peers, colleagues and companies through their innovative and motivational approaches to addressing the industry’s myriad challenges.

Ms. Chitwood was selected from a group of nominations submitted by industry peers. A panel of PharmaVOICE editors evaluated the submissions based on nominees' ability to inspire, motivate and influence corporate leadership, research and development, technology, creativity, marketing and strategy. Ms. Chitwood is featured in the July/August 2016 issue of PharmaVOICE.

About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: Investor.Relations@incresearch.com Press/Media Contacts: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: Corporate.Communications@incresearch.com

Source:INC Research, LLC